atezolizumab

A monoclonal antibody that targets programmed death-ligand 1 (CD274 ANTIGEN) and is used to treat urothelial carcinoma, the most common type of bladder cancer.

Also Known As:

MPDL-3280A; MPDL3280A; RG-7446; RG7446; Tecentriq; anti-PDL1; immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer

Networked: 1813 relevant articles (330 outcomes, 570 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Powles, Thomas: 39 articles (03/2022 - 11/2014)
2.	Ballinger, Marcus: 23 articles (01/2022 - 04/2016)
3.	Loriot, Yohann: 19 articles (01/2022 - 11/2014)
4.	Kowanetz, Marcin: 19 articles (01/2021 - 11/2014)
5.	Sandler, Alan: 19 articles (01/2021 - 04/2016)
6.	Emens, Leisha A: 18 articles (01/2022 - 05/2015)
7.	Hegde, Priti S: 18 articles (01/2021 - 11/2014)
8.	Hopkins, Ashley M: 17 articles (03/2022 - 08/2019)
9.	Sorich, Michael J: 17 articles (03/2022 - 08/2019)
10.	Mariathasan, Sanjeev: 17 articles (01/2022 - 05/2016)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 05/01/2022 - "This retrospective study included 239 patients with advanced hepatocellular carcinoma receiving atezolizumab/Bev from September 2020 to June 2021 at 16 different institutions in Japan. " 01/01/2021 - "An update on atezolizumab for hepatocellular carcinoma." 01/01/2021 - "Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait." 10/01/2023 - "The Epidemio Liver Immunotherapy Tecentriq outcome research (ELITor) retrospective study, based on real-world data from the Carcinome HépatocellulaIrE en France (CHIEF) French cohort of hepatocellular carcinoma patients, aimed to get insight into the treatment patterns, the sociodemographic, clinical, biological, and etiological characteristics, and the quality of life of patients with unresectable hepatocellular carcinoma. " 06/14/2021 - "We report here a case of a 62-year-old male with hepatocellular carcinoma who presented with upper GI bleed after atezolizumab therapy. "
2.	Neoplasms (Cancer) 01/01/2021 - "The tumour-to-muscle and tumour-to-blood ratios were comparable with/without atezolizumab (P<0.04) but were significantly lowered when co-injected with excess NM-01 (P=0.04 and P=0.01, respectively.) The blood clearance of [99mTc]-NM-01 is bi-phasic; consisting of an initial fast washout phase with half-life of 2.1 min and a slower clearance phase with half-life of 25.4 min. In an intravenous extended single-dose toxicity study, no treatment-related changes were observed and the maximum tolerated dose of [99mTc]-NM-01 was 2.58 mg/kg. [99mTc]-NM-01 has suitable properties as a potential candidate for SPECT/CT imaging of PD-L1 assessment in cancer patients." 11/01/2021 - "Notably, the combination of core fucosylation inhibitor 2F-Fuc and anti-PDL1 results in enhanced therapeutic efficacy in B7H3-positive TNBC tumors. " 11/01/2021 - "Here, we report the development of the anti-PD-L1 antibody drug Maxatezo, a glycosylated version of Atezolizumab, with no ADCC activity, better thermo-stability, and significantly improved anti-tumor activity in vivo. " 01/01/2020 - "Anti-tumor efficacy of anti-PD1, but not anti-PDL1 or anti-CTLA4, was significantly enhanced by ZVex/mTRP1 and HPB vaccination. " 01/01/2021 - "Patients with ECOG PS 2 had clinical features typically associated with aggressive disease; median overall survival was 2.3 months versus 10.0 months in patients with ECOG PS0/1. Patients with PD-L1 expression on ≥5% of tumor-infiltrating immune cells tended to have better outcomes than those with <5% PD-L1 expression, although conclusions on the relative efficacy of atezolizumab cannot be drawn from this single-arm study. "
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/16/2023 - "Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. " 01/01/2021 - "The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the safety and efficacy of atezolizumab monotherapy in a clinically diverse population of patients with previously treated non-small cell lung cancer, including those not eligible for pivotal trials. " 01/01/2023 - "Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials." 01/01/2022 - "Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study." 01/01/2021 - "Efficacy of atezolizumab to treat non-small-cell lung cancer: a meta-analysis based on randomized clinical trials."
4.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/01/2022 - "Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). " 01/01/2022 - "A 69-year-old man with advanced small-cell lung cancer achieved partial remission after 3 courses of immunochemotherapy that included atezolizumab. " 11/27/2020 - "The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). " 01/01/2020 - "Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer." 11/01/2019 - "Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)."
5.	Triple Negative Breast Neoplasms 11/01/2020 - "Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?" 01/01/2020 - "Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)." 01/01/2020 - "Herein, we review the pharmacodynamic and pharmacokinetic properties of atezolizumab, its safety and efficacy data from early clinical trials and summarize data from Phase III IMpassion130 trial, prompting FDA and EMA approval of atezolizumab in metastatic triple-negative breast cancer. " 12/27/2019 - "Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)." 08/01/2023 - "Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1."

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	pembrolizumab
3.	Immune Checkpoint Inhibitors
4.	Carboplatin (JM8)
5.	130-nm albumin-bound paclitaxel
6.	Nivolumab
7.	B7-H1 Antigen
8.	Platinum
9.	durvalumab
10.	Sorafenib (BAY 43-9006)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Immunotherapy
4.	Neoadjuvant Therapy
5.	Cystectomy